301096 百诚医药
已收盘 09-11 15:00:00
资讯
新帖
简况
股市必读：百诚医药中报 - 第二季度单季净利润同比下降138.28%
证券之星 · 08-28
股市必读：百诚医药中报 - 第二季度单季净利润同比下降138.28%
百诚医药（301096）2026年中报简析：净利润同比下降48.43%，公司应收账款体量较大
证券之星 · 08-28
百诚医药（301096）2026年中报简析：净利润同比下降48.43%，公司应收账款体量较大
百诚医药(301096)6月30日股东户数1.17万户，较上期增加4.48%
证券之星 · 08-27
百诚医药(301096)6月30日股东户数1.17万户，较上期增加4.48%
图解百诚医药中报：第二季度单季净利润同比下降138.28%
证券之星 · 08-27
图解百诚医药中报：第二季度单季净利润同比下降138.28%
百诚医药（301096）披露2026年半年度报告，8月26日股价下跌2.68%
证券之星 · 08-26
百诚医药（301096）披露2026年半年度报告，8月26日股价下跌2.68%
百诚医药（301096）披露全资子公司部分药品中选国家药品集中采购公告，8月11日股价上涨2.36%
证券之星 · 08-11
百诚医药（301096）披露全资子公司部分药品中选国家药品集中采购公告，8月11日股价上涨2.36%
百诚医药最新公告：全资子公司西格列汀二甲双胍缓释片中选第十二批国家药品集采
证券之星 · 08-11
百诚医药最新公告：全资子公司西格列汀二甲双胍缓释片中选第十二批国家药品集采
股市必读：百诚医药（301096）7月31日董秘有最新回复
证券之星 · 08-03
股市必读：百诚医药（301096）7月31日董秘有最新回复
百诚医药（301096）披露创新药BIOS0635-048片获临床试验批准通知书，7月27日股价上涨2.08%
证券之星 · 07-27
百诚医药（301096）披露创新药BIOS0635-048片获临床试验批准通知书，7月27日股价上涨2.08%
百诚医药最新公告：创新药BIOS0635-048片获临床试验批准通知书
证券之星 · 07-27
百诚医药最新公告：创新药BIOS0635-048片获临床试验批准通知书
7月17日百诚医药（301096）龙虎榜数据：机构净卖出2228.36万元，北向资金净买入472.86万元
证券之星 · 07-17
7月17日百诚医药（301096）龙虎榜数据：机构净卖出2228.36万元，北向资金净买入472.86万元
百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书
智通财经 · 07-17
百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书
百诚医药最新公告：创新药BIOS0629-109片获临床试验批准
证券之星 · 07-02
百诚医药最新公告：创新药BIOS0629-109片获临床试验批准
百诚医药：公司目前暂未布局青蒿素相关原材料或产品
证券之星 · 06-30
百诚医药：公司目前暂未布局青蒿素相关原材料或产品
百诚医药：决定终止筹划控制权变更事项
证券之星 · 06-30
百诚医药：决定终止筹划控制权变更事项
每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划
证券之星 · 06-21
每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划
百诚医药涨7.23%，东吴证券一个月前给出“买入”评级
证券之星 · 06-04
百诚医药涨7.23%，东吴证券一个月前给出“买入”评级
百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%
证券之星 · 06-02
百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%
开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及
21世纪经济报道 · 06-01
开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
21世纪经济报道 · 06-01
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
加载更多
公司概况
公司名称：
杭州百诚医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-12-20
主营业务：
杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。
发行价格：
79.60
{"stockData":{"symbol":"301096","market":"SZ","secType":"STK","nameCN":"百诚医药","latestPrice":48.08,"timestamp":1789110201000,"preClose":48.5,"halted":0,"volume":5616260,"delay":0,"changeRate":-0.0087,"floatShares":83114599,"shares":109000000,"eps":-0.8414,"marketStatus":"已收盘","change":-0.42,"latestTime":"09-11 15:00:00","open":48.66,"high":50.6,"low":47.8,"amount":276000000,"amplitude":0.0577,"askPrice":48.09,"askSize":8,"bidPrice":48.08,"bidSize":7,"shortable":0,"etf":0,"ttmEps":-0.8414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":48.5,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":53.35,"lowLimit":43.65,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":109228284,"isCdr":false,"pbRate":2.13,"roa":"--","roe":"0.06%","epsLYR":-0.83,"committee":0.504587,"marketValue":5252000000,"turnoverRate":0.0676,"status":1,"floatMarketCap":3996000000},"requestUrl":"/m/hq/s/301096","defaultTab":"news","newsList":[{"id":"2662603187","title":"股市必读：百诚医药中报 - 第二季度单季净利润同比下降138.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662603187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662603187?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:00","pubTimestamp":1787871639,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润为-1121.47万元，同比下降138.28%；扣非净利润为-2920.02万元，同比下降219.42%。公司公告汇总：董事会审议通过使用剩余超募资金13,991.99万元永久补充流动资金，并定于2026年9月15日召开临时股东大会审议该议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800013457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662298039","title":"百诚医药（301096）2026年中报简析：净利润同比下降48.43%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2662298039","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662298039?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:47","pubTimestamp":1787870838,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百诚医药发布2026年中报。截至本报告期末，公司营业总收入3.04亿元，同比下降8.4%，归母净利润159.77万元，同比下降48.43%。按单季度数据看，第二季度营业总收入1.44亿元，同比下降29.29%，第二季度归母净利润-1121.47万元，同比下降138.28%。本报告期百诚医药公司应收账款体量较大，当期应收账款占最新年报营业总收入比达77.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800013248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703778","title":"百诚医药(301096)6月30日股东户数1.17万户，较上期增加4.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703778","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703778?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:18","pubTimestamp":1787825882,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百诚医药披露，截至2026年6月30日公司股东户数为1.17万户，较3月31日增加502.0户，增幅为4.48%。在医疗服务行业个股中，百诚医药股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.75万户。从股价来看，2026年3月31日至2026年6月30日，百诚医药区间涨幅为12.49%，在此期间股东户数增加502.0户，增幅为4.48%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749703","title":"图解百诚医药中报：第二季度单季净利润同比下降138.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749703","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749703?lang=zh_cn&edition=full","pubTime":"2026-08-27 03:11","pubTimestamp":1787771475,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药2026年中报显示，上半年度公司主营收入3.04亿元，同比下降8.4%；归母净利润159.77万元，同比下降48.43%；扣非净利润-2150.14万元，同比下降83.3%；其中2026年第二季度，公司单季度主营收入1.44亿元，同比下降29.29%；单季度归母净利润-1121.47万元，同比下降138.28%；单季度扣非净利润-2920.02万元，同比下降219.42%；负债率33.51%，投资收益485.78万元，财务费用943.21万元，毛利率47.13%。财报数据概要请见下图:本文数据来源于百诚医药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700007256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662474831","title":"百诚医药（301096）披露2026年半年度报告，8月26日股价下跌2.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662474831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662474831?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:46","pubTimestamp":1787755575,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，百诚医药报收于46.78元，较前一交易日下跌2.68%，最新总市值为51.1亿元。该股当日开盘47.64元，最高48.27元，最低46.35元，成交额达1亿元，换手率为2.57%。近日，百诚医药披露《2026年半年度报告》。报告显示，本报告期营业收入为304,442,101.61元，较上年同期下降8.40%；归属于上市公司股东的净利润为1,597,715.67元，同比下降48.43%；扣除非经常性损益后的净利润为-21,501,418.06元，同比下降83.30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600053887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916103","title":"百诚医药（301096）披露全资子公司部分药品中选国家药品集中采购公告，8月11日股价上涨2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916103?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:10","pubTimestamp":1786457412,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，百诚医药报收于46.84元，较前一交易日上涨2.36%，最新总市值为51.16亿元。公司于近日披露《关于全资子公司部分药品中选国家药品集中采购的公告》。公告显示，杭州百诚医药科技股份有限公司全资子公司浙江赛默制药有限公司参与国家组织的第十二批药品集中采购，西格列汀二甲双胍缓释片两个规格产品中选。目前采购协议签订等后续事项仍存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999534","title":"百诚医药最新公告：全资子公司西格列汀二甲双胍缓释片中选第十二批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658999534?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:41","pubTimestamp":1786441266,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司全资子公司浙江赛默制药有限公司参与第十二批全国药品集中采购，西格列汀二甲双胍缓释片中选。该药品适用于成人2型糖尿病患者，规格为磷酸西格列汀50mg/100mg联合盐酸二甲双胍500mg/1000mg。2025年度该产品暂未实现销售收入，若后续签订采购合同并实施，将有利于产品放量销售及市场开拓，对公司未来经营业绩产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100028662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656634373","title":"股市必读：百诚医药（301096）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656634373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656634373?lang=zh_cn&edition=full","pubTime":"2026-08-03 03:38","pubTimestamp":1785699494,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，百诚医药报收于37.82元，上涨5.17%，换手率4.32%，成交量3.59万手，成交额1.36亿元。董秘最新回复投资者： 公司与耀速科技的合作主要涉及哪些方面董秘： 尊敬的投资者您好，在前沿技术、产业资源与研发能力上，公司与包括耀速科技在内的行业伙伴一直保持着开放性的交流与探索。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654468140","title":"百诚医药（301096）披露创新药BIOS0635-048片获临床试验批准通知书，7月27日股价上涨2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654468140","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654468140?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:20","pubTimestamp":1785162035,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，百诚医药报收于39.2元，较前一交易日上涨2.08%，最新总市值为42.82亿元。该股当日开盘38.38元，最高40.77元，最低38.12元，成交额达1.63亿元，换手率为4.98%。公司于近日披露《关于创新药BIOS0635-048片获得临床试验批准通知书的公告》。公司近期业绩不会因此次获批产生重大影响，后续将按法规推进临床试验，研发过程存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","301096","BK0216","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654382016","title":"百诚医药最新公告：创新药BIOS0635-048片获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654382016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654382016?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:28","pubTimestamp":1785144490,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司自主研发的创新药BIOS0635-048片获得国家药品监督管理局临床试验批准通知书，同意本品单药在晚期实体瘤中开展临床试验。该药物为新型小分子抑制剂，拟用于多种实体瘤的治疗，目前全球尚无针对该靶点的药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700022436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","BK1574","BK0216","159992","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740103","title":"7月17日百诚医药（301096）龙虎榜数据：机构净卖出2228.36万元，北向资金净买入472.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652740103?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:46","pubTimestamp":1784281612,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月17日公布的交易公开信息显示，百诚医药因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月17日收盘，百诚医药报收于41.59元，下跌20.0%，跌停，换手率10.57%，成交量8.79万手，成交额3.93亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出2228.36万元，北向资金合计净买入472.86万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700032802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652640164","title":"百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2652640164","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652640164?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:34","pubTimestamp":1784280869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百诚医药(301096.SZ)发布公告，公司全资子公司浙江赛默制药有限公司近日收到国家药品监督管理局核准签发的左乙拉西坦缓释颗粒的药品注册证书。该药品为2.2类改良型新药，适用于12岁及以上的癫痫患者部分性发作的加用治疗。相比已上市的普通片和缓释片等剂型，缓释颗粒更适用于儿童和吞咽困难患者，提高了患者的依从性，有较为明显的临床优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648501800","title":"百诚医药最新公告：创新药BIOS0629-109片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648501800","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648501800?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:31","pubTimestamp":1782988287,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司与浙江众神创新医药科技有限公司合作研发的创新药BIOS0629-109片获得国家药监局临床试验批准通知书，同意开展单药在晚期恶性肿瘤的临床试验。该药品为1类化学药，是一种新型XPO1抑制剂。公司与众神创新于2025年11月达成独家授权合作，公司负责研发、临床试验及注册申报等工作，上市后享有销售额10%的提成收益。本次获批对近期业绩无重大影响，后续临床试验及上市存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200034479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","BK0216","BK1574","159992","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647813355","title":"百诚医药：公司目前暂未布局青蒿素相关原材料或产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2647813355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647813355?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:33","pubTimestamp":1782790436,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司有青蒿素相关产原材料或产品吗？百诚医药回复：尊敬的投资者您好，公司目前暂未布局青蒿素相关原材料或产品，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000017951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581369","title":"百诚医药：决定终止筹划控制权变更事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647581369?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:33","pubTimestamp":1782790436,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：实控人此前曾增持股份，本次股权转让中，交易方报价溢价约20%-30%，未达到实控人50%左右的预期溢价。请问终止转让，是否是基于对公司后续发展的信心，坚持认可公司更高价值？百诚医药回复：尊敬的投资者您好，相关交易方经慎重考虑、磋商，认真听取各方意见，决定终止筹划控制权变更事项。公司严格按照信息披露的相关规定履行信息披露义务，尚未公开披露交易方报价等信息，请以公司公开披露信息为准。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000017952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645096152","title":"每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2645096152","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645096152?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:13","pubTimestamp":1781982789,"startTime":"0","endTime":"0","summary":"本周关注点来自公司公告汇总：百诚医药审议通过2026年限制性股票激励计划（草案）及相关议案。公司公告汇总杭州百诚医药科技股份有限公司于2026年6月17日召开2026年第一次临时股东会，采用现场与网络投票结合方式，审议通过选举第四届董事会非独立董事、续聘天健会计师事务所、2026年限制性股票激励计划（草案）及其摘要、实施考核管理办法、提请股东会授权董事会办理股权激励相关事宜等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640534461","title":"百诚医药涨7.23%，东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2640534461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640534461?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:46","pubTimestamp":1780562784,"startTime":"0","endTime":"0","summary":"今日百诚医药（301096）涨7.23%，收盘报58.74元。2026年4月29日，东吴证券研究员朱国广,苏丰,邹行健发布了对百诚医药的研报《2025年报&2026一季报点评：26Q1利润超预期，创新管线持续推进》，该研报对百诚医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为69.92%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西部证券的吴天昊。百诚医药（301096）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400028748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911335","title":"百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640911335?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:42","pubTimestamp":1780393356,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，百诚医药报收于56.35元，较前一交易日下跌3.51%，最新总市值为61.55亿元。该股当日开盘58.0元，最高60.41元，最低56.31元，成交额达4.15亿元，换手率为8.56%。近日，杭州百诚医药科技股份有限公司披露《2026年限制性股票激励计划（草案）》。公告显示，本次激励计划拟采用第二类限制性股票形式，股票来源为定向发行A股普通股，拟授予不超过500.00万股，占公司总股本的4.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798290","title":"开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798290","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640798290?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"公告一出，引发市场对这家CRO龙头易主的种种猜想。财务数据显示，2025年，百诚医药实现营业总收入6.78亿元，同比下降15.45%；归母净利润则连续第二年出现亏损，亏损额从上年同期的5274.28万元扩大至9039.55万元。公司2026年一季度实现净利润1281.25万元，成功扭亏为盈。公司称，业绩改善主要得益于仿制药CRO/CDMO业务逐步企稳、集采中标品种商业化稳步开展以及降本增效措施取得成效。Wind数据显示，百诚医药股东户数月1.12万名。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwist5284387.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwist5284387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981365","title":"医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981365","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640981365?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272073,"startTime":"0","endTime":"0","summary":"药械审批国家医保局发布2026年国家医保目录调整工作方案5月31日，国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755285483.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755285483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","301096","600521","BK0196","BK0070","BK0175","IPOS","301263","BK0028","BK0096","600196","BK0185","BK0060","BK0012","BK0250","BK0188","600513","300562","BK0109","BK0187","BK0114","BK0201","BK0183","BK0239","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789267714609,"stockEarnings":[{"period":"1week","weight":0.1061},{"period":"1month","weight":-0.0006},{"period":"3month","weight":-0.11},{"period":"6month","weight":-0.0805},{"period":"1year","weight":-0.2359},{"period":"ytd","weight":-0.1586}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州百诚医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"11718人(较上一季度增加4.48%)","perCapita":"7092股","listingDate":"2021-12-20","address":"浙江省杭州市临平区临平街道绿洲路159号","registeredCapital":"10922万元","survey":" 杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。","listedPrice":79.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百诚医药,301096,百诚医药股票,百诚医药股票老虎,百诚医药股票老虎国际,百诚医药行情,百诚医药股票行情,百诚医药股价,百诚医药股市,百诚医药股票价格,百诚医药股票交易,百诚医药股票购买,百诚医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}